Oral Presentations:
- Abstract Title: Assessing the impact of SAT-3247 on muscle force in a mouse model of FSHD
- Presenter: Phil Lambert, PhD, Satellos Chief Scientific Officer
- Time: Wednesday, Mar. 11, 9:30 – 9:45 a.m. ET
- Session: Novel Therapeutics Approaches
- Location: Florida 1-3
- Abstract Title: A Phase 1a/b open label study of SAT-3247 in healthy volunteers and adult patients with Duchenne Muscular Dystrophy (Poster #394 O)
- Presenter: Wildon Farwell, MD, MPH, Satellos Chief Medical Officer
- Time: Wednesday, Mar. 11, 11:30 – 11:45 a.m. ET
- Session: Clinical Trial Updates
- Location: Florida 4
Poster Presentations:
Tuesday, March 10, 10:30 a.m. – 1:30 p.m., 4 – 4:30 p.m., 6 – 8 p.m.
Conference Exhibit Hall
- Title: A Phase 1a/b open label study of SAT-3247 in healthy volunteers and adult patients with Duchenne Muscular Dystrophy
- Presenter: Wildon Farwell, MD, Satellos Chief Medical Officer
- Poster Number: 394 O
- Title: TRAILHEAD: An Open-Label, Phase 2 Study Evaluating Long-Term Safety and Efficacy of SAT-3247 in Adults with Duchenne Muscular Dystrophy (DMD)
- Presenter: Kristiana Salmon, Satellos Clinical Scientist
- Poster Number: 487 LB
- Title: Regenerative Index Quantitation Reveals a Reduced Regenerative Potential in Duchenne Muscular Dystrophy from 7-11 years of age
- Presenter: Ryan Mitchell, PhD, Satellos Senior VP, Head of Corporate Development
- Poster Number: 282 T